Dr Susan Cleator is a Consultant Clinical Oncologist based at Charing Cross Hospital, part of Imperial College Healthcare NHS Foundation Trust.
Dr Cleator trained at Oxford University and Hospitals, and undertook her oncology training at the Charing Cross, Hammersmith, Mount Vernon and The Royal Marsden Hospitals. During this period she also spent three years working full-time on her PhD project at the Institute of Cancer Research and Royal Marsden Hospital. This focused on identifying a molecular assay for predicting the response of breast cancers to chemotherapy. She has published on this and a number of other aspects of oncology.
She works closely with her surgical colleagues at St Mary's hospital where she is responsible for the chemotherapy and radiotherapy aspects of their treatment, specializing in breast, colorectal and lymphomatous cancers.
Dr Cleator was previously a member of Breast Cancer Studies Group (overseeing Breast Cancer National Research portfolio) and is a member of the American Association Cancer Physicians and the British Medical Association.
Professor Ricky Sharma is a Professor of Clinical Oncology based at University College London.
Prof Sharma graduated in medicine from the University of Cambridge and then trained in general internal medicine, medical oncology and radiation oncology. He completed a PhD on DNA damage repair. Since 2006, he has led a research group at the University of Oxford.
He is the Laboratory Group Leader of the Translational DNA Repair Group at the CRUK/MRC Oxford Institute for Radiation Oncology at the University of Oxford. He is also a Higher Education Funding Council for England (HEFCE) Clinical Senior Lecturer at the University of Oxford, an Honorary Consultant in Clinical Oncology at the Oxford University Hospitals NHS Trust, and a Senior Research Fellow at Harris Manchester College, University of Oxford. His specialisms include radiotherapy, chemotherapy, bowel cancer, liver cancer, and liver-directed therapies.
Dr Sharma has a prominent national and international profile in his field and co-chairs the Early Phase Trials Workstream of the NCRI Clinical Translational Radiotherapy (CTRad) Group and is the Chief Investigator of the NCRN FOXFIRE, a multi-centre, clinical randomised clinical trial testing a new combination of chemotherapy and selective internal radiotherapy in the treatment of liver metastases from colorectal cancer. He is an examiner for Royal College of Radiologists (Clinical Oncology) a member of Faculty Board and a prominent member of several working groups within the college, particularly on interventional oncology and undergraduate education. He also tutors at Harris Manchester College and St Catherine's College, University of Oxford, Dr Sharma is a module leader for postgraduate teaching of radiobiology and oncology and is leading the development of a national mentorship scheme for clinical oncology trainees. He was appointed as Chair of the Teaching Committee of the Oncology Department at the University of Oxford in May 2011.
Dr Sharma is a Fellow of both the Royal College of Physicians and the Royal College of Radiologists.
Professor Justin Stebbing is a Consultant Medical Oncologist based at Imperial College Healthcare NHS Trust in London.
Professor Stebbing trained in medicine at Trinity College Oxford, where he gained a triple first class degree. After completion of junior doctor posts in Oxford, he undertook a residency at The Johns Hopkins Hospital in the US, returning to London to continue his training in oncology at The Royal Marsden and St Bartholomew’s Hospitals. Professor Stebbing’s PhD research investigated the interplay between the immune system and cancer.
Professor Stebbing has published over 500 peer-reviewed papers in journals such as the Lancet, New England Journal, Blood, the Journal of Clinical Oncology, Annals of Internal Medicine, as well as writing for national newspapers and presenting new data on optimal cancer therapies at major international conferences. His focus is on new therapies in cancer, and the systemic management of patients with a variety of solid malignancies, including a number of new biomarker-based approaches, with an emphasis on circulating tumour cells. His laboratory work is concentrated on new druggable target discovery.
He is a member of the Royal College of Physicians, the American Board of Internal Medicine and the Royal College of Pathologists, and sits on the advisory Boards of five biotechnology companies. He chairs the World Vaccine Congress and is on the editorial board of a number of world leading general medical and cancer journals such as the Journal of Clinical Oncology and Oncogene and writes BMA guidelines for several cancers.
Dr Hendrik-Tobias Arkenau is Medical Director at Sarah Cannon Research UK in London.
Dr Arkenau received his medical and postgraduate degree at the Medical School Hanover, Germany, and completed his internship and specialist training in oncology in 2007. Before being appointed as, he was Senior Clinical Fellow at the Royal Marsden Hospital and team leader for Early Drug Development at the Prince of Wales Clinical School at the University of New South Wales, Sydney, Australia.
He has obtained ASCO, AACR and ESMO Merit Awards and languages spoken are English and German
Dr David Propper is a Consultant Medical Oncologist based at Barts and The London NHS Trust.
Dr Propper trained in medical oncology at the Imperial Cancer Research Fund Medical Oncology Unit in Oxford and received major trial research experience there. He subsequently spent time at the Lombardi Cancer Centre Georgetown Washington DC, USA.
Dr Propper has interests in translational research, early phase trials and the introduction of new therapeutic agents.
Dr Chris Cottrill is a Consultant Clinical Oncologist based at Barts Cancer Centre (St Bartholomews Hospital) in London.
Dr Cottrill specialises in Breast and Gastrointestinal (oesophagus, stomach, pancreas, colon, rectum and anus) cancers and has a specialist interest in stereotactic radiosurgery (CyberKnife treatment). He has a particular interest in combined modality therapy (combination chemo-radiotherapy). He has been a Consultant at St Bartholomew's Hospital for 10 years and is experienced in all aspects of the chemotherapy and radiotherapy treatment of Breast and Gastrointestinal cancers.
Within the field of radiotherapy Dr Cottrill has a specialist interest in combined chemo-radiotherapy, intensity-modulated radiotherapy (IMRT, RapidArc, VMAT) and image-guided radiotherapy (IGRT). He is fully accredited in the use of CyberKnife stereotactic ablative radiotherapy (SABR) at Barts Hospital, the London Clinic and the Harley Street Clinic CyberKnife units.
Since 2000 Dr Cottrill has lectured annually on international postgraduate courses in the field of evidence-based radiation therapy for the European Society for Radiotherapy and Oncology (ESTRO).
Dr Tony Dhillon is a Consultant Medical Oncologist based at The Royal Surrey County Hospital NHS Foundation Trust.
Dr Dhillon has been a consultant medical oncologist since 2010. He is a senior lecturer in Oncology at the University of Surrey and Imperial College London, looking into new treatment in GI cancers.
He treats colorectal, liver, pancreas, biliary, NET and GIST tumours.
Dr Dhillon trained in medical oncology at Imperial College Healthcare NHS Trust hospitals (Hammersmith and Charing Cross Hospitals) and Chelsea and Westminster and the Royal Free Hospital.
He has a PhD from Imperial College London in the field of cancer cell signaling funded by a CR-UK clinical training fellowship.
He has been a Wellcome Trust fellow at the University of Oxford and a lecturer in physiology at the University of Oxford.
Dr Shabbir Susnerwala is a Consultant Clinical Oncologist based at The Rosemere Cancer Centre at the Royal Preston Hospital.
Dr Susnerwala qualified in oncology at Bombays largest cancer hospital, the Tata Memorial Hospital and was appointed as a consultant oncologist in 1989. He decided to move to the UK in 1992 and joined Europe's largest cancer centre, The Christie Hospital, Manchester where he consolidated his oncological experience. In 1996 he was appointed as Consultant Clinical Oncologist at the newly established Rosemere Cancer Centre.
He specialises in the treatment of Colorectal, Breast and Urological cancers. His expertise have been widely sought for many years both in clinical practice and education and he has held a number of positions that reflect this. These include Clinical Director for Oncology Services, Educational Supervisor, College Tutor (Royal College of Radiologists), Overseas Doctors Mentor, Member of Postgraduate Committee (Royal Preston Hospital), Audit Lead for Oncology, Lead Cancer Clinician for Lancashire Teaching Hospital chain and is a member of the Clinical Governance Committee for Oncology.
Dr Susnerwala is a member of The Royal College of Radiologists and speaks English, Gujarati and Hindi.
Dr Sebastian Cummins is a Consultant Clinical Oncologist based at St. Luke's Cancer Centre at The Royal Surrey County Hospital in Guildford.
Dr Cummins specialises in upper and lower gastrointestinal malignancies and hepato-pancreatobiliary (liver and pancreas) malignancy.
He is based at St Lukes' Cancer Centre, from where he is involved in a wide range of research based protocols, both with regards to novel biological therapies and technical radiotherapy development.
Dr Ramkumar Shanmugasundaram is a Consultant Clinical Oncologist based at University Hospital Southampton NHS trust.
Ramkumar trained in India as a radiation oncologist from 1994 – 1997. He contuined his training as a Specialist Registrar in Wessex Clinical Oncology Rotation 2004-2009 and obtained Certificate of Completion of Training Fellowship in IMRT & IGRT at Royal Marsden Hospital in 2009.
He specialises in chemotherapy and high precision radiotherapy for head and neck cancer, skull base tumours and colorectal cancer. Dr Shanmugasundaram also has experience in proton therapy for skull base tumours.
He is a member of the Royal College of Radiologists, Royal College of Physicians, Medical Protection Society, British Medical Association, British Association of Head and Neck Oncologists, and the European Society for Therapeutic Radiology and Oncology.